Amyloid-β PET Scan Results Disclosure and Care-Partner Emotional Well-Being Over Time.

ABSTRACT:

Background

Diagnostic tests, such as amyloid-β positron emission tomography (PET) scans, can increase appropriate therapeutic management for the underlying causes of cognitive decline. To evaluate the full utility of this diagnostic tool, information is needed on whether results from amyloid-β PET scans influence care-partner outcomes.

Objective

This study examines the extent to which previous disclosure of elevated amyloid (suggestive of Alzheimer's disease (AD) etiology) versus not-elevated amyloid (not suggestive of AD etiology) is associated with changes in care-partner wellbeing.

Methods

The study used data derived from a national longitudinal survey of Medicare beneficiaries (n = 921) with mild cognitive impairment (MCI) or dementia and their care-partners. Care

SUBMITTER: Shepherd-Banigan ME 

PROVIDER: S-EPMC9749778 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature